Craig-Hallum Rates MapLight Therapeutics (MPLT) buy
Analyst Adam Vogel reaffirms a buy rating and a $40 price target on MapLight Therapeutics, keeping a positive view as other firms adjust their outlooks, a 27.47% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Craig-Hallum rated MapLight Therapeutics, Inc. ($MPLT) "buy" with a $40 price target on June 23, 2026.
Since the rating, $MPLT is up 25.1% after 1 week, up 23.0% after 1 month and down 73.1% to date (from the $28.64 close on Jun 23, 2026).
MPLT
MapLight Therapeutics, Inc.
Key Points
- Craig-Hallum analyst Adam Vogel reiterated a buy rating on MapLight Therapeutics, Inc. (NasdaqGS: MPLT) with a $40.00 price target on June 23, 2026.
- Craig-Hallum's $40 price target implies 27.47% upside from MapLight Therapeutics, Inc.'s ($MPLT) current $31.38 share price.
- The stock traded around $31.38 on Tuesday, sitting well above its 52-week low of $9.10 and near its high of $40.43.
- Wall Street opinion remains mixed on the clinical-stage biotech firm, with recent updates from firms like Guggenheim, Needham, and UBS.
Get $MPLT trade alerts by text
We text you when insiders, Congress or big funds trade $MPLT. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated MapLight Therapeutics, Inc. alert may contain errors. Disclosures
Craig-Hallum Keeps Positive Stance on MapLight Therapeutics
On June 23, 2026, Craig-Hallum analyst Adam Vogel reaffirmed a buy rating on MapLight Therapeutics, Inc. (NasdaqGS: MPLT) along with a $40.00 price target. This call keeps the firm in the bull camp as the clinical-stage biopharmaceutical company advances treatments for central nervous system disorders. Wall Street's broader coverage reveals a split picture, with various firms adjusting their targets up and down over the summer.
Craig-Hallum vs. the S&P 500
Hypothetical returns from Craig-Hallum's disclosed trades, not real profit or advice. How we model this.
Wall Street Ratings and Recent Analyst Updates
Other major financial institutions have taken different views on the biotech firm in recent weeks. On October 6, 2026, Guggenheim initiated coverage with a neutral rating. Before that, Needham maintained a buy rating on August 31, 2026, while lowering its price target to $43.00 from $45.00. UBS shifted its stance on August 10, 2026, downgrading the stock to a neutral rating and cutting its target sharply to $13.00 from $52.00. Back on July 28, 2026, Canaccord Genuity kept a buy rating but moved its target to $24.00 from $43.00, Morgan Stanley moved to an equal-weight rating with a $21.00 target, and HC Wainwright & Co. maintained a buy rating with a $26.00 target. Earlier in July, Canaccord Genuity and UBS also adjusted targets as the stock moved through its yearly range.
MapLight Therapeutics Stock Performance and Valuation
Shares changed hands at $31.38 on Tuesday. The stock has experienced wide swings, touching a 52-week low of $9.10 and climbing near its peak of $40.43. Because the company is still focused on clinical trials and is not yet profitable, it lacks a meaningful price-to-earnings ratio. Its upcoming financial update is slated for November 12, 2026, when management will share its next quarterly progress report.
$MPLT price target
MapLight Therapeutics, Inc. daily closes and this analyst's $40 target. Not advice.
Inside the Clinical Pipeline
MapLight Therapeutics works on developing targeted therapies for patients suffering from difficult central nervous system disorders. Its pipeline features candidates like ML-007C-MA for schizophrenia and Alzheimer's disease psychosis, alongside treatments for social communication deficits in autism and motor symptoms in Parkinson's disease. The company relies on a proprietary platform designed to map neural circuits linked directly to specific diseases.
Looking Ahead for MPLT
Investors will keep tracking clinical trial updates and regulatory milestones as the company moves toward its late-year earnings release. While firms like Craig-Hallum see strong upside toward the $40.00 mark, other analysts have taken a cautious approach following recent valuation shifts. As always, ratings and targets reflect individual firm perspectives and do not guarantee future price movements.
Related Filing Alerts
Source: Craig-Hallum's rating change on $MPLT (Jun 23, 2026). Written by software, not financial advice. How we make alerts